Sharma Ajaykumar N, da Costa e Silva Bruno Fernando Borges, Soares Jair C, Carvalho André F, Quevedo Joao
Translational Psychiatry Program, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX 77054, USA; Center of Excellence on Mood Disorders, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX 77054, USA.
Translational Psychiatry Program, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX 77054, USA.
J Affect Disord. 2016 Jun;197:9-20. doi: 10.1016/j.jad.2016.02.067. Epub 2016 Mar 2.
The neurotrophin hypothesis of major depressive disorder (MDD) postulates that this illness results from aberrant neurogenesis in brain regions that regulates emotion and memory. Notwithstanding this theory has primarily implicated BDNF in the neurobiology of MDD. Recent evidence suggests that other trophic factors namely GDNF, VEGF and IGF-1 may also be involved.
The present review aimed to critically summarize evidence regarding changes in GDNF, IGF-1 and VEGF in individuals with MDD compared to healthy controls. In addition, we also evaluated the role of these mediators as potential treatment response biomarkers for MDD.
A comprehensive review of original studies studies measuring peripheral, central or mRNA levels of GDNF, IGF-1 or VEGF in patients with MDD was conducted. The PubMed/MEDLINE database was searched for peer-reviewed studies published in English through June 2nd, 2015.
Most studies reported a reduction in peripheral GDNF and its mRNA levels in MDD patients versus controls. In contrast, IGF-1 levels in MDD patients compared to controls were discrepant across studies. Finally, most studies reported high peripheral VEGF levels and mRNA expression in MDD patients compared to healthy controls.
GDNF, IGF-1 and VEGF levels and their mRNA expression appear to be differentially altered in MDD patients compared to healthy individuals, indicating that these molecules might play an important role in the pathophysiology of depression and antidepressant action of therapeutic interventions.
重度抑郁症(MDD)的神经营养因子假说假定,这种疾病是由调节情绪和记忆的脑区神经发生异常所致。尽管该理论主要认为脑源性神经营养因子(BDNF)与MDD的神经生物学有关,但最近的证据表明,其他营养因子,即胶质细胞源性神经营养因子(GDNF)、血管内皮生长因子(VEGF)和胰岛素样生长因子-1(IGF-1)也可能参与其中。
本综述旨在批判性地总结与MDD患者相比,健康对照者中GDNF、IGF-1和VEGF变化的相关证据。此外,我们还评估了这些介质作为MDD潜在治疗反应生物标志物的作用。
对测量MDD患者外周、中枢或GDNF、IGF-1或VEGF mRNA水平的原始研究进行了全面综述。在PubMed/MEDLINE数据库中搜索截至2015年6月2日以英文发表的同行评审研究。
大多数研究报告称,与对照组相比,MDD患者外周GDNF及其mRNA水平降低。相比之下,各研究中MDD患者与对照组的IGF-1水平存在差异。最后,大多数研究报告称,与健康对照组相比,MDD患者外周VEGF水平和mRNA表达较高。
与健康个体相比,MDD患者的GDNF、IGF-1和VEGF水平及其mRNA表达似乎有不同程度的改变,这表明这些分子可能在抑郁症的病理生理学和治疗干预的抗抑郁作用中发挥重要作用。